Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bristol pays $2bn for infectious disease therapeutics firm Inhibitex

Executive Summary

In the second major HCV acquisition announced in the last few months, Bristol-Myers Squibb Co. is paying $2bn for publicly traded Inhibitex Inc. (mainly HCV drug candidates), which gets $26 in cash per share, a 151% premium.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register